CBPartners Invited to Lead Workshop on Orphan Disease Drug Access and Pricing at 2013 ISPOR International Meeting

Share Article

CBPartners Invited to Lead Workshop on Orphan Disease Drug Access and Pricing at 2013 ISPOR International Meeting

Policy on access and value assessment of these unique therapies has yet to evolve....

CBPartners, one of the world’s leading authorities on the development of pricing and market access strategy for orphan disease designated products, was officially selected by ISPOR (International Society for Pharmacoeconomics and Outcomes Research) to lead a workshop during the organisation’s international five-day conference in New Orleans. The workshop will take place on Tuesday, May 21, 2013 at 17:00 CDT, and will focus on current global pricing and market access policies, and how they do and do not accommodate the unique nature of orphan disease designated drugs.

The session will be led by Ms. Monica Martin de Bustamante, Managing Director of CBPartners. She will introduce the major issues, and Dr. Rachel Beckerman, Principal of Value Demonstration at CBPartners, will lead a review of the global health technology assessment (HTA) landscape, and the specific bylaws in place for orphan and ultra-orphan diseases. Dr. Corinna Sorenson, Research Fellow of Health Policy at the London School of Economics will provide rationale for orphan disease access policies, with a particular focus on major European markets. Ms. Meghan Gallagher, Director of Evidence Translation at Sanofi, will provide the drug developer’s perspective on orphan disease drug access. Finally, Mr. Cyrus A. Chowdhury, CEO and Managing Director of CBPartners will provide additional global perspective on orphan disease drug brands and lessons learned in established and emerging markets.

“During the past decade, the number of therapies with first-indications for orphan and ultra-orphan diseases has steadily increased, however policy on access and value assessment of these unique therapies has yet to evolve,” explains Ms. Martin de Bustamante. “It has gradually become apparent that HTA agencies are not going to make it easy for these products to achieve access.”

“At very least,” Mr. Chowdhury adds, “health economic models are being requested, and in some cases, their outputs are being used as part of a pricing and reimbursement evaluation process designed for therapies with substantially larger patient populations and very different disease dynamics.”

Manufacturers of these agents have lobbied for policy-makers to adapt their evaluation process to meet the specifications of orphan diseases. “Many companies have worked to educate policy-makers, and change is gradual, but eventual,” states Ms. Gallagher.

The discussion will be facilitated by orphan disease experts. For a copy of the materials used during this workshop, please visit http://www.cbpartners.com or email info@cbpartners.com after the workshop.

About CBPartners
CBPartners is a leading global strategy consulting firm focusing on healthcare issues for a variety of clients, including biopharmaceutical / pharmaceutical companies, medical device companies and government health authorities. Headquartered in New York City, CBPartners maintains a continuous throughput of local market intelligence updates from advisors throughout over 70 countries. CBPartners provides expertise through five practice areas including Pricing and Market Access, Value Demonstration, Portfolio Optimisation, Commercial Planning, and Government Policy Advisory.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Cyrus Chowdhury
CB Partners
+1 347 221 9536
Email >
Follow us on
Visit website